MX2013004417A - Peptidos wdhd1 y vacunas que los incluyen. - Google Patents

Peptidos wdhd1 y vacunas que los incluyen.

Info

Publication number
MX2013004417A
MX2013004417A MX2013004417A MX2013004417A MX2013004417A MX 2013004417 A MX2013004417 A MX 2013004417A MX 2013004417 A MX2013004417 A MX 2013004417A MX 2013004417 A MX2013004417 A MX 2013004417A MX 2013004417 A MX2013004417 A MX 2013004417A
Authority
MX
Mexico
Prior art keywords
peptides
same
vaccines including
peptide
wdhd1
Prior art date
Application number
MX2013004417A
Other languages
English (en)
Inventor
Yusuke Nakamura
Takuya Tsunoda
Sachiko Yoshimura
Tomohisa Watanabe
Ryuji Osawa
Original Assignee
Oncotherapy Science Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncotherapy Science Inc filed Critical Oncotherapy Science Inc
Publication of MX2013004417A publication Critical patent/MX2013004417A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)

Abstract

Se describen vacunas de péptido contra el cáncer. En particular, se proporcionan péptidos de epítopo aislados o fragmentos inmunogénicos derivados de la SEQ ID NO: 32, que enlazan a un antígeno HLA e inducen linfocitos T citotóxicos (CTL). La secuencia de aminoácido del péptido de interés puede modificarse opcionalmente con la sustitución, eliminación, inserción, o adición de uno, dos, o varias secuencias de aminoácido. También se proporcionan composiciones farmacéuticas y métodos para tratar el cáncer que incluyen tales péptidos.
MX2013004417A 2010-10-21 2011-10-20 Peptidos wdhd1 y vacunas que los incluyen. MX2013004417A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40551710P 2010-10-21 2010-10-21
PCT/JP2011/005866 WO2012053206A1 (en) 2010-10-21 2011-10-20 Wdhd1 peptides and vaccines including the same

Publications (1)

Publication Number Publication Date
MX2013004417A true MX2013004417A (es) 2013-05-22

Family

ID=45974936

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013004417A MX2013004417A (es) 2010-10-21 2011-10-20 Peptidos wdhd1 y vacunas que los incluyen.

Country Status (14)

Country Link
US (1) US9056890B2 (es)
EP (1) EP2630238A4 (es)
JP (1) JP2014504146A (es)
KR (1) KR20130138804A (es)
CN (1) CN103270156B (es)
AU (1) AU2011319359A1 (es)
BR (1) BR112013009526A2 (es)
CA (1) CA2815102A1 (es)
IL (1) IL225552A0 (es)
MX (1) MX2013004417A (es)
RU (1) RU2013123045A (es)
SG (1) SG189222A1 (es)
TW (1) TW201216982A (es)
WO (1) WO2012053206A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2895600T3 (da) 2012-09-11 2020-04-27 Onco Therapy Science Inc Ube2t-peptider og vacciner, der indeholder disse
SI3573600T1 (sl) 2017-01-25 2022-07-29 Ose Immunotherapeutics Postopek za proizvodnjo obstojne emulzije za dostavo peptida

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4406607B2 (ja) * 2002-08-26 2010-02-03 オンコセラピー・サイエンス株式会社 ペプチド及びこれを含む医薬
CA2606227A1 (en) 2005-04-28 2006-11-02 Mcgill University Compounds and methods for modulating cadherin-mediated processes
CN101835893A (zh) * 2007-08-24 2010-09-15 肿瘤疗法科学股份有限公司 癌症相关基因cdca5、epha7、stk31和wdhd1
US20100159513A1 (en) 2008-12-20 2010-06-24 E. I. Du Pont De Nemours And Compnay Genes that increase peptide production

Also Published As

Publication number Publication date
AU2011319359A1 (en) 2013-05-02
JP2014504146A (ja) 2014-02-20
US9056890B2 (en) 2015-06-16
CN103270156B (zh) 2015-09-02
EP2630238A4 (en) 2014-02-19
IL225552A0 (en) 2013-06-27
KR20130138804A (ko) 2013-12-19
US20130309259A1 (en) 2013-11-21
SG189222A1 (en) 2013-06-28
WO2012053206A1 (en) 2012-04-26
TW201216982A (en) 2012-05-01
CA2815102A1 (en) 2012-04-26
EP2630238A1 (en) 2013-08-28
BR112013009526A2 (pt) 2017-05-02
RU2013123045A (ru) 2014-11-27
CN103270156A (zh) 2013-08-28

Similar Documents

Publication Publication Date Title
PH12019502194A1 (en) Novel immunotherapy against several tumors including gastrointestinal and gastric cancer
NZ733168A (en) Novel immunotherapy against several tumors, such as lung cancer, including nsclc
UA103751C2 (ru) Иммуногенный пептид для иммунотерапии
MX2011007963A (es) Peptidos neil3 y vacunas que incluyen los mismos.
EP3412304A3 (en) Hla-a24 agonist epitopes of muc1-c oncoprotein and compositions and methods of use
MX2011008763A (es) Peptidos foxm1 y vacunas que contienen los mismos.
MX2019011621A (es) Inmunoterapia novedosa contra varios tumores, tales como cancer de pulmon, que incluye cancer de pulmon de celula no pequeña (nsclc).
NZ609916A (en) Hla-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof
JP2014502961A5 (es)
MX355759B (es) Peptidos topk y vacunas que incluyen los mismos.
MX2013014489A (es) Peptidos sema5b y vacunas que incluyen los mismos.
EP2528937A4 (en) MODIFIED MELK PEPTIDES AND ASSOCIATED VACCINES
MY166516A (en) Tomm34 peptides and vaccines including the same
MX2011008917A (es) Peptidos vangl1 y vacunas que incluyen los mismos.
EP3556857A3 (en) Cdc45l peptides and vaccines including the same
NZ592461A (en) Rab6kifl/kif20a epitope peptide and vaccines containing the same
MX2013004417A (es) Peptidos wdhd1 y vacunas que los incluyen.
MX2012006770A (es) Peptidos tmem22 y vacunas que incluyen los mismos.
BR112013009276A2 (pt) peptídeos de c18orf54 e vacinas incluindo os mesmos
MY170949A (en) A peptide capable of binding with a human leukocyte antigen (hla) molecule, a cancer vaccine derived from said peptide and use of said cancer vaccine
NZ746513A (en) Novel peptides and combination of peptides for use in immunotherapy against various tumors

Legal Events

Date Code Title Description
FA Abandonment or withdrawal